sofosbuvir has been researched along with Cardiac Toxicity in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Batista, R; Blanchet, B; Cabanes, L; Chouchana, L; Goldwasser, F; Huillard, O; Khoudour, N; Monribot, A; Pallet, N; Préta, LH; Sogni, P; Thomas-Schoemann, A | 1 |
| Costa, C; D'Ascoli, GL; De Rosa, S; Focà, A; Indolfi, C; Liberto, MC; Mazzitelli, M; Pisani, V; Raffetti, E; Sabatino, J; Strazzulla, A; Torti, C | 1 |
2 other study(ies) available for sofosbuvir and Cardiac Toxicity
| Article | Year |
|---|---|
Cardiac toxicity associated with pharmacokinetic drug-drug interaction between crizotinib and sofosbuvir/velpatasvir: A case report.
Topics: Aged; Antiviral Agents; Carcinoma, Non-Small-Cell Lung; Cardiotoxicity; Crizotinib; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lung Neoplasms; Macrocyclic Compounds; Male; Sofosbuvir | 2023 |
Evaluation of cardiac function by global longitudinal strain before and after treatment with sofosbuvir-based regimens in HCV infected patients.
Topics: Aged; Cardiotoxicity; Chronic Disease; Drug Therapy, Combination; Echocardiography; Female; Heart Function Tests; Hepatitis C; Humans; Longitudinal Studies; Male; Middle Aged; Sofosbuvir; Treatment Outcome; Ventricular Dysfunction, Left; Ventricular Function, Left | 2018 |